Amyotrophic Lateral Sclerosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Amyotrophic Lateral Sclerosis Treatment Market Report is Segmented by Treatment Type (Medication and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD Million) for the Above Segments.

Amyotrophic Lateral Sclerosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Amyotrophic Lateral Sclerosis Treatment Market Size

Global Amyotrophic Lateral Sclerosis Treatment Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 0.9 Billion
Market Size (2030) USD 1.21 Billion
CAGR (2025 - 2030) 5.94 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Global Amyotrophic Lateral Sclerosis Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Amyotrophic Lateral Sclerosis Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Global Amyotrophic Lateral Sclerosis Treatment Market Analysis

The Global Amyotrophic Lateral Sclerosis Treatment Market size is estimated at USD 0.9 billion in 2025, and is expected to reach USD 1.21 billion by 2030, at a CAGR of 5.94% during the forecast period (2025-2030).

In recent years, the amyotrophic lateral sclerosis (ALS) treatment market has been driven by increasing awareness of advancements in neurobiology and growing investments in the development of innovative therapies. Furthermore, progress in stem cell and gene therapies is creating significant opportunities for future treatment solutions, thereby accelerating market growth.

Several initiatives have been taken by the government authoritative bodies to fast-track the development of novel drugs and treatments which is projected to drive the market growth. For instance, in 2023, the National Institute of Neurological Disorders and Stroke (NINDS) outlined strategic priorities for ALS research, aiming to speed up the creation of effective interventions for ALS diagnosis, treatment, management, prevention, and potential cures. These priorities were shaped with insights from scientists, clinicians, advocates, individuals impacted by ALS, and the broader public. Additionally, under the "Accelerating Access to Critical Therapies for ALS Act," NINDS is funding research to provide investigational new drugs to ALS patients not qualifying for clinical trials. Such proactive government measures are set to significantly boost market growth for ALS treatments.

Moreover, increased investments in research and the approval of new drugs, including Qalsody, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta, have played a pivotal role in propelling market growth. For example, in April 2023, Biogen Inc. received the U.S. Food and Drug Administration (FDA) approval for its QALSODY (tofersen) 100 mg/15mL injection. This drug is specifically designed for treating amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. These groundbreaking product launches not only enhance patient outcomes but also broaden treatment options, further driving market expansion.

Furthermore, increased awareness of Amyotrophic Lateral Sclerosis (ALS) among healthcare providers and the general public leads to earlier and more accurate diagnoses, enabling timely intervention and treatment. This heightened awareness and improved diagnostics result in a larger patient population seeking specialized therapies, thereby driving growth in the ALS treatment market. For example, in June 2024, the ALS Association chose InnoVision Marketing Group as its agency to create media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS). The goal is to raise awareness and highlight the need for community support for those living with ALS. As awareness grows among patients and healthcare professionals about ALS and available treatments, diagnosis rates are rising, driving demand for ALS drugs. This increased awareness is likely to lead to earlier diagnosis and treatment, resulting in better patient outcomes and increased market growth.

Therefore, owing to the aforementioned factors such as the growing government initiatives, approvals and launches by market players, and increased awareness and diagnosis, the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is estimated to restrain market growth.

Global Amyotrophic Lateral Sclerosis Treatment Industry Overview

The amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, CRISPR Therapeutics, Boehringer Ingelheim International GmbH and ANNEXON, INC.

Global Amyotrophic Lateral Sclerosis Treatment Market Leaders

  1. Mitsubishi Tanabe Pharma Corporation

  2. CORESTEM, Inc

  3. BrainStorm Cell Limited

  4. Amylyx Pharmaceuticals Inc.

  5. Biogen

  6. *Disclaimer: Major Players sorted in no particular order
Amyotrophic Lateral Sclerosis Treatment Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Global Amyotrophic Lateral Sclerosis Treatment Market News

  • May 2024: NeuroSense Therapeutics, a company developing novel treatments for severe neurodegenerative diseases partnered with Boston-based company PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis (ALS). The collaboration aims to develop the Phase III trial protocol for NeuroSense’s ALS therapy PrimeC (celecoxib and ciprofloxacin). The company plans to use the analysis to inform trial design and patient enrolment, as well as ensure cost-effectiveness.
  • May 2024: Biogen received approval from the European Commission (EC) for its QALSODY (tofersen) medication for the treatment of adults with amyotrophic lateral sclerosis (ALS). QALSODY is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Global Amyotrophic Lateral Sclerosis Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Incidence and Prevalence of Amyotrophic Lateral Sclerosis
    • 4.2.2 Recent Advancements in Research and Development, Particularly in the Areas of Drug Discovery and Gene Therapy
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Treatment Type
    • 5.1.1 Medication
    • 5.1.2 Stem Cell Therapy
    • 5.1.3 Other Treatment Types
  • 5.2 By End-user
    • 5.2.1 Hospital
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Other End-users
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mitsubishi Tanabe Pharma Corporation
    • 6.1.2 Sun Pharmaceutical Industries Ltd.
    • 6.1.3 CORESTEM, Inc
    • 6.1.4 BrainStorm Cell Limited
    • 6.1.5 Amylyx Pharmaceuticals Inc.
    • 6.1.6 AB Science
    • 6.1.7 Ionis Pharmaceuticals
    • 6.1.8 Biohaven Pharmaceutical
    • 6.1.9 Biogen
    • 6.1.10 CRISPR Therapeutics
    • 6.1.11 Boehringer Ingelheim International GmbH
    • 6.1.12 ANNEXON, INC.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Amyotrophic Lateral Sclerosis Treatment Industry Segmentation

As per the scope of the report, amyotrophic lateral sclerosis (ALS) is a neurological disorder and fatal disease that affects nerve cells in the neuron and spinal control which controls voluntary muscle movement in the human body. This disorder affects neurons which results in the blockage of messages between muscles and the brain. The amyotrophic lateral sclerosis treatment market is segmented by treatment type, end-user, and geography. By treatment type, the market is segmented into medication, stem cell therapy, and other treatment types. The others segment is further bifurcated into respiratory therapy and chemotherapy. By end-user the market is segmented into hospitals, diagnostic centers, and other end-users. The others segment is further bifurcated into research and academic institutes and homecare settings. The report also covers the market size and forecasts for the amyotrophic lateral sclerosis treatment market in 17 countries across major regions. For each segment, the market sizing and forecasts have been done on the basis of value (USD).

By Treatment Type Medication
Stem Cell Therapy
Other Treatment Types
By End-user Hospital
Diagnostic Centers
Other End-users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Global Amyotrophic Lateral Sclerosis Treatment Market Research FAQs

How big is the Global Amyotrophic Lateral Sclerosis Treatment Market?

The Global Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 0.9 billion in 2025 and grow at a CAGR of 5.94% to reach USD 1.21 billion by 2030.

What is the current Global Amyotrophic Lateral Sclerosis Treatment Market size?

In 2025, the Global Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 0.9 billion.

Who are the key players in Global Amyotrophic Lateral Sclerosis Treatment Market?

Mitsubishi Tanabe Pharma Corporation, CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc. and Biogen are the major companies operating in the Global Amyotrophic Lateral Sclerosis Treatment Market.

Which is the fastest growing region in Global Amyotrophic Lateral Sclerosis Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Amyotrophic Lateral Sclerosis Treatment Market?

In 2025, the North America accounts for the largest market share in Global Amyotrophic Lateral Sclerosis Treatment Market.

What years does this Global Amyotrophic Lateral Sclerosis Treatment Market cover, and what was the market size in 2024?

In 2024, the Global Amyotrophic Lateral Sclerosis Treatment Market size was estimated at USD 0.85 billion. The report covers the Global Amyotrophic Lateral Sclerosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Amyotrophic Lateral Sclerosis Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Amyotrophic Lateral Sclerosis Treatment Industry Report

The report on the Amyotrophic Lateral Sclerosis (ALS) market provides an in-depth industry analysis, focusing on various treatment types such as medication and others. The market is segmented by distribution channels including hospital pharmacies, retail pharmacies, and others, and covers geographical regions like North America, Europe, Asia-Pacific, Middle East and Africa, and South America.

The industry report highlights the market trends and market growth, offering a detailed market forecast and market overview. It also includes an industry outlook and industry trends, presenting valuable market data and industry statistics. The report example and report PDF provide a comprehensive review of market segmentation and market value.

Furthermore, the industry research delves into market predictions and market review, identifying market leaders and market outlook. The report also features insights into industry sales and industry size, supported by industry information and market analysis. The report underscores the importance of market research and industry reports, offering a thorough industry overview and market forecast.

In summary, the ALS market report is an essential resource for understanding the industry's growth rate, market leaders, and market trends. It provides a clear picture of market segmentation and market value, supported by detailed industry analysis and market data. The report is an invaluable tool for research companies seeking to gain a deeper understanding of the ALS market, offering a comprehensive market review and industry outlook.